Activation of the estrogen-signaling pathway by p21WAF1/CIP1 in estrogen receptor-negative breast cancer cells

被引:29
作者
Chen, XM
Danes, C
Lowe, M
Herliczek, TW
Keyomarsi, K
机构
[1] Wadsworth Ctr, Div Mol Med, Albany, NY USA
[2] SUNY Albany, Dept Biomed Sci, Albany, NY USA
关键词
D O I
10.1093/jnci/92.17.1403
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Estrogen stimulates the proliferation of cells in normal mammary glands and most estrogen receptor (ER)positive mammary carcinomas by binding to the ER and promoting the transcription of ER-responsive genes. In cells with functional ERs, estrogen mediates the transition of cells from the G(1) to S phase of the cell cycle. Several cell cycle regulatory proteins have been implicated in the ER-signaling pathway involved in estrogen-mediated growth stimulation and antiestrogen-mediated growth arrest, We sought to determine whether p21, a cyclin-dependent kinase inhibitor, is a component of this pathway and, if so, whether it can mediate estrogen's action in ER-negative breast cancer cells. Methods: We overexpressed p21 with a tetracycline-inducible system in ER-negative, p21-negative breast cancer cells. Activity of the ER-signaling pathway was monitored in transient transfection assays by using constructs in which the ER promoter or the estrogen-response element (ERE) controls Luciferase expression. The growth-modulating effects of estradiol and antiestrogens on p21-overexpressing clones were assessed. All P values are from two-sided tests. Results: A strong positive association was found between the expression of p21 and ER in nine breast cancer cell lines and in tumor samples from 60 patients with breast cancer (P<.001). Overexpression of p21 in a p21-negative, ER-negative cell line induced both the ER and ERE promoters in an estrogen-responsive manner. Last, stable p21 clones that also lack the expression of wild-type ER were responsive to the growth-inhibitory effects of ICI 182,780, a potent antiestrogen, and the growth-stimulatory effects of 17 beta-estradiol, Conclusion: The ability of p21 to mediate the activation of the estrogen-signaling pathway in ER-negative tumor cells suggests that p21 plays a novel role in this pathway, a finding that also has important clinical implications.
引用
收藏
页码:1403 / 1413
页数:11
相关论文
共 69 条
[1]  
Bacus SS, 1996, ONCOGENE, V12, P2535
[2]  
BACUS SS, 1993, PATHOL ANNU, V28, P179
[3]   Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line [J].
Barboule, N ;
Chadebech, P ;
Baldin, V ;
Vidal, S ;
Valette, A .
ONCOGENE, 1997, 15 (23) :2867-2875
[4]   STEROID-HORMONE RECEPTORS - MANY ACTORS IN SEARCH OF A PLOT [J].
BEATO, M ;
HERRLICH, P ;
SCHUTZ, G .
CELL, 1995, 83 (06) :851-857
[5]   ENDOGENOUS HORMONES AND BREAST-CANCER RISK [J].
BERNSTEIN, L ;
ROSS, RK .
EPIDEMIOLOGIC REVIEWS, 1993, 15 (01) :48-65
[6]  
BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116
[7]   Bypass of senescence after disruption of p21(CIP1/WAF1) gene in normal diploid human fibroblasts [J].
Brown, JP ;
Wei, WY ;
Sedivy, JM .
SCIENCE, 1997, 277 (5327) :831-834
[8]   CHEMOSENSITIVITY TESTING OF HUMAN-LUNG CANCER CELL-LINES USING THE MTT ASSAY [J].
CARMICHAEL, J ;
MITCHELL, JB ;
DEGRAFF, WG ;
GAMSON, J ;
GAZDAR, AF ;
JOHNSON, BE ;
GLATSTEIN, E ;
MINNA, JD .
BRITISH JOURNAL OF CANCER, 1988, 57 (06) :540-547
[9]   Auto-regulation of the estrogen receptor promoter [J].
Castles, CG ;
Oesterreich, S ;
Hansen, R ;
Fuqua, SAW .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1997, 62 (2-3) :155-163
[10]   UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent [J].
Chen, XM ;
Lowe, M ;
Keyomarsi, K .
ONCOGENE, 1999, 18 (41) :5691-5702